» Articles » PMID: 24371137

GPR37 Protein Trafficking to the Plasma Membrane Regulated by Prosaposin and GM1 Gangliosides Promotes Cell Viability

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2013 Dec 28
PMID 24371137
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The subcellular distribution of the G protein-coupled receptor GPR37 affects cell viability and is implicated in the pathogenesis of parkinsonism. Intracellular accumulation and aggregation of GPR37 cause cell death, whereas GPR37 located in the plasma membrane provides cell protection. We define here a pathway through which the recently identified natural ligand, prosaposin, promotes plasma membrane association of GPR37. Immunoabsorption of extracellular prosaposin reduced GPR37(tGFP) surface density and decreased cell viability in catecholaminergic N2a cells. We found that GPR37(tGFP) partitioned in GM1 ganglioside-containing lipid rafts in the plasma membrane of live cells. This partitioning required extracellular prosaposin and was disrupted by lipid raft perturbation using methyl-β-cyclodextrin or cholesterol oxidase. Moreover, complex formation between GPR37(tGFP) and the GM1 marker cholera toxin was observed in the plasma membrane. These data show functional association between GPR37, prosaposin, and GM1 in the plasma membrane. These results thus tie together the three previously defined components of the cellular response to insult. Our findings identify a mechanism through which the receptor's natural ligand and GM1 may protect against toxic intracellular GPR37 aggregates observed in parkinsonism.

Citing Articles

GPR37 and its neuroprotective mechanisms: bridging osteocalcin signaling and brain function.

Bian X, Wang Y, Zhang W, Ye C, Li J Front Cell Dev Biol. 2024; 12:1510666.

PMID: 39633709 PMC: 11614806. DOI: 10.3389/fcell.2024.1510666.


Intranasal administration of recombinant prosaposin attenuates neuronal apoptosis through GPR37/PI3K/Akt/ASK1 pathway in MCAO rats.

Yu J, Li J, Matei N, Wang W, Tang L, Pang J Exp Neurol. 2023; 373:114656.

PMID: 38114054 PMC: 10922973. DOI: 10.1016/j.expneurol.2023.114656.


Orphan G Protein-Coupled Receptor GPR37 as an Emerging Therapeutic Target.

Bolinger A, Frazier A, La J, Allen J, Zhou J ACS Chem Neurosci. 2023; 14(18):3318-3334.

PMID: 37676000 PMC: 11144446. DOI: 10.1021/acschemneuro.3c00479.


GPR37L1 controls maturation and organization of cortical astrocytes during development.

Nguyen T, Camp C, Doan J, Traynelis S, Sloan S, Hall R Glia. 2023; 71(8):1921-1946.

PMID: 37029775 PMC: 10315172. DOI: 10.1002/glia.24375.


Mouse Mutants of and Receptor Genes: Disease Modeling Applications.

Massimi M, Di Pietro C, La Sala G, Matteoni R Int J Mol Sci. 2022; 23(8).

PMID: 35457105 PMC: 9025225. DOI: 10.3390/ijms23084288.


References
1.
Ulrich M, Kappel C, Beaudouin J, Hezel S, Ulrich J, Eils R . Tropical--parameter estimation and simulation of reaction-diffusion models based on spatio-temporal microscopy images. Bioinformatics. 2006; 22(21):2709-10. DOI: 10.1093/bioinformatics/btl456. View

2.
Campana W, Mohiuddin L, Misasi R, OBrien J, Calcutt N . Prosaposin-derived peptides enhanced sprouting of sensory neurons in vitro and induced sprouting at motor endplates in vivo. J Peripher Nerv Syst. 2001; 5(3):126-30. DOI: 10.1046/j.1529-8027.2000.00019.x. View

3.
Navarro A, Zapata R, Canela E, Mallol J, Lluis C, Franco R . Epidermal growth factor (EGF)-induced up-regulation and agonist- and antagonist-induced desensitization and internalization of A1 adenosine receptors in a pituitary-derived cell line. Brain Res. 1999; 816(1):47-57. DOI: 10.1016/s0006-8993(98)01062-2. View

4.
MORITA F, Wen T, Tanaka J, Hata R, Desaki J, Sato K . Protective effect of a prosaposin-derived, 18-mer peptide on slowly progressive neuronal degeneration after brief ischemia. J Cereb Blood Flow Metab. 2001; 21(11):1295-302. DOI: 10.1097/00004647-200111000-00005. View

5.
Schneider J, Gollomp S, Sendek S, Colcher A, Cambi F, Du W . A randomized, controlled, delayed start trial of GM1 ganglioside in treated Parkinson's disease patients. J Neurol Sci. 2012; 324(1-2):140-8. PMC: 3532888. DOI: 10.1016/j.jns.2012.10.024. View